FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 1309 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Severe mental illness linked to low attendance at cancer screening May 4, 2023 Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II... July 27, 2026 Osteoblasts Are “Warrior” Bone Cells That Can Suppress Bone-Metastatic Breast Cancer... June 10, 2019 Wawa Employee Saves Life Of Customer Who Stopped Breathing After A... January 20, 2022 Load more HOT NEWS EMA Adopts a New Pharmaceutical Form of Selumetinib Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms Improving Care for Underserved People With Cancer and Evaluating Delays in... Representation, retention and hope – how a mentorship scheme is helping...
